CR20230261A - Cocristal de un inhibidor de cdk - Google Patents
Cocristal de un inhibidor de cdkInfo
- Publication number
- CR20230261A CR20230261A CR20230261A CR20230261A CR20230261A CR 20230261 A CR20230261 A CR 20230261A CR 20230261 A CR20230261 A CR 20230261A CR 20230261 A CR20230261 A CR 20230261A CR 20230261 A CR20230261 A CR 20230261A
- Authority
- CR
- Costa Rica
- Prior art keywords
- cocrystal
- cdk inhibitor
- relates
- cdk7
- fumarate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202041055174 | 2020-12-18 | ||
| PCT/IB2021/061895 WO2022130304A1 (en) | 2020-12-18 | 2021-12-17 | Cocrystal of a cdk inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20230261A true CR20230261A (es) | 2023-10-04 |
Family
ID=80001496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20230261A CR20230261A (es) | 2020-12-18 | 2021-12-17 | Cocristal de un inhibidor de cdk |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20240059669A1 (https=) |
| EP (1) | EP4263534A1 (https=) |
| JP (1) | JP2023554492A (https=) |
| KR (1) | KR20230159363A (https=) |
| CN (1) | CN116685326A (https=) |
| AU (1) | AU2021402415A1 (https=) |
| CA (1) | CA3202198A1 (https=) |
| CL (1) | CL2023001753A1 (https=) |
| CO (1) | CO2023009368A2 (https=) |
| CR (1) | CR20230261A (https=) |
| DO (1) | DOP2023000126A (https=) |
| EC (1) | ECSP23054131A (https=) |
| IL (1) | IL303738A (https=) |
| MX (1) | MX2023007218A (https=) |
| PE (1) | PE20231441A1 (https=) |
| TW (1) | TW202241881A (https=) |
| WO (1) | WO2022130304A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022084930A2 (en) * | 2020-10-22 | 2022-04-28 | Aurigene Discovery Technologies Limited | Cancer therapy using a combination of cdk7 inhibitor with an anti-microtubule agent |
| US12084453B2 (en) | 2021-12-10 | 2024-09-10 | Incyte Corporation | Bicyclic amines as CDK12 inhibitors |
| WO2023224961A1 (en) | 2022-05-16 | 2023-11-23 | Exelixis, Inc. | Cancer therapy using a combination of a cdk7 inhibitor with an oral serd |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| CN118772106A (zh) * | 2024-06-07 | 2024-10-15 | 山东大学 | 伊马替尼-没食子酸共晶、其溶剂化物、制备方法和应用 |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3302448T1 (sl) | 2015-06-04 | 2024-03-29 | Aurigene Oncology Limited | Substituirani heterociklični derivati kot inhibitorji cdk |
-
2021
- 2021-12-17 PE PE2023001908A patent/PE20231441A1/es unknown
- 2021-12-17 AU AU2021402415A patent/AU2021402415A1/en not_active Abandoned
- 2021-12-17 EP EP21848027.5A patent/EP4263534A1/en active Pending
- 2021-12-17 WO PCT/IB2021/061895 patent/WO2022130304A1/en not_active Ceased
- 2021-12-17 TW TW110147455A patent/TW202241881A/zh unknown
- 2021-12-17 MX MX2023007218A patent/MX2023007218A/es unknown
- 2021-12-17 CN CN202180085401.XA patent/CN116685326A/zh active Pending
- 2021-12-17 CA CA3202198A patent/CA3202198A1/en active Pending
- 2021-12-17 US US18/257,962 patent/US20240059669A1/en active Pending
- 2021-12-17 JP JP2023537470A patent/JP2023554492A/ja active Pending
- 2021-12-17 CR CR20230261A patent/CR20230261A/es unknown
- 2021-12-17 KR KR1020237024297A patent/KR20230159363A/ko active Pending
- 2021-12-17 IL IL303738A patent/IL303738A/en unknown
-
2023
- 2023-06-15 CL CL2023001753A patent/CL2023001753A1/es unknown
- 2023-06-16 DO DO2023000126A patent/DOP2023000126A/es unknown
- 2023-07-14 CO CONC2023/0009368A patent/CO2023009368A2/es unknown
- 2023-07-18 EC ECSENADI202354131A patent/ECSP23054131A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2023009368A2 (es) | 2023-09-29 |
| KR20230159363A (ko) | 2023-11-21 |
| ECSP23054131A (es) | 2023-09-29 |
| EP4263534A1 (en) | 2023-10-25 |
| WO2022130304A1 (en) | 2022-06-23 |
| CN116685326A (zh) | 2023-09-01 |
| MX2023007218A (es) | 2023-07-27 |
| CA3202198A1 (en) | 2022-06-23 |
| JP2023554492A (ja) | 2023-12-27 |
| US20240059669A1 (en) | 2024-02-22 |
| IL303738A (en) | 2023-08-01 |
| TW202241881A (zh) | 2022-11-01 |
| PE20231441A1 (es) | 2023-09-14 |
| DOP2023000126A (es) | 2023-11-30 |
| AU2021402415A1 (en) | 2023-07-06 |
| CL2023001753A1 (es) | 2024-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023007218A (es) | Cocristal de un inhibidor de cinasa dependiente de ciclina (cdk). | |
| ZA202403388B (en) | Small molecules for treatement of cancer | |
| MX2024007058A (es) | Derivados de 5,6,7,8-tetrahidro-2,6-naftiridina como terapeuticos contra el cancer. | |
| SA522433155B1 (ar) | مركبات ثلاثية الحلقة مستبدلة | |
| ZA202201499B (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| MX2023003627A (es) | Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead para el tratamiento del cancer. | |
| PH12022551014A1 (en) | Substituted tricyclic compounds | |
| PH12022552261A1 (en) | Crystalline hydrate of a jak inhibitor compound | |
| DE602004015810D1 (de) | Substituierte isochinolinderivate und anwendungsverfahren | |
| MX2022015531A (es) | Derivado de piridina-pirimidina, metodo de preparacion y uso farmaceutico del mismo. | |
| EA200970611A1 (ru) | Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы | |
| ZA202007566B (en) | 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof | |
| MX2020010942A (es) | Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales. | |
| AU2020288567A8 (en) | Pyrrolopyrimidine compound and use thereof | |
| WO2022268935A3 (en) | Process for the preparation of nlrp3 inhibitors | |
| NZ762437A (en) | Novel heterocyclic compounds as cdk8/19 inhibitors | |
| MY195576A (en) | Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof | |
| MX2025001865A (es) | Compuestos de piridinona sustituida como inhibidores de cbl-b | |
| WO2023102162A8 (en) | Novel hdac inhibitors and therapeutic use thereof | |
| MX2020002630A (es) | Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta. | |
| MX2023007150A (es) | Compuestos de pirazol que contienen boro, composiciones que los comprenden, métodos y usos de los mismos. | |
| WO2023205595A3 (en) | Egfr inhibitors in cancer treatment | |
| MX2023014784A (es) | Preparacion de derivados de compuestos 1,2-diaminoheterociclicos sustituidos y su uso como agentes farmaceuticos. | |
| EP4620940A3 (en) | Synthesis of (+)-cannabinoids and their therapeutic effects | |
| EP4248960A3 (en) | Novel triterpene derivatives as hiv inhibitors |